tyrosinase + MAGE-3 + GnTV

This is a **synthetic multiepitope peptide vaccine** formulation composed of peptides derived from **tyrosinase**, **MAGE-3** (Melanoma Antigen Gene A3), and **GnTV** (N-acetylglucosaminyltransferase V, also referred to as GnT-V). The vaccine is designed to induce **cellular immune responses**, especially cytotoxic T lymphocyte (CTL) activity, against tumors expressing these antigens, primarily **melanoma**. Administration is typically combined with immune adjuvants such as **KLH (keyhole limpet hemocyanin)** and **GM-CSF (granulocyte-macrophage colony-stimulating factor)** to enhance immunogenicity. The approach aims to stimulate T-cell responses recognizing tumor-associated antigens, promoting anti-tumor immunity in cancer patients, especially those with advanced melanoma[3][5][8]. The vaccine does not have a unique commercial or code name, and it is used primarily in investigational settings.